Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

A monoclonal antibody — a protein created in a lab which mimics the work of a natural antibody — could be highly effective in ...